Báo cáo khoa học: Alpha-oxidation of 3-methyl-substituted fatty acids and its thiamine dependence pptx

REVIEW ARTICLE
Alpha-oxidation of 3-methyl-substituted fatty acids
and its thiamine dependence
Minne Casteels, Veerle Foulon, Guy P. Mannaerts and Paul P. Van Veldhoven
Afdeling Farmacologie, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Belgium
3-Methyl-branched fatty acids, as phytanic acid, undergo
peroxisomal a-oxidation in which they are shortened by 1
carbon atom. This process includes four steps: activation,
2-hydroxylation, thiamine pyrophosphate dependent
cleavage and aldehyde dehydrogenation. The thiamine
pyrophosphate dependence of the third step is unique in
peroxisomal mammalian enzymology. Human pathology
due to a deficient alpha-oxidation is mostly linked to
mutations in the gene coding for the second enzyme of the
sequence, phytanoyl-CoA hydroxylase.
Keywords: alpha-oxidation; thiamine pyrophosphate; per-
oxisomes; lyase; Adult Refsum Disease.
Introduction
a-Oxidation is the process in which fatty acids are shortened
at the carboxyl-end by one carbon atom. For 3-methyl-
branched fatty acids, this is the preferred pathway as their
breakdown by b-oxidation is impossible. Indeed, the
3-methyl-branch precludes the third step of b-oxidation,
the dehydrogenation step. Phytanic acid (3,7,11,15-tetra-
methylhexadecanoic acid) is at present the only established
physiological substrate of a-oxidation in humans [1,2].
Phytanic acid is derived from phytol, the isoprenoid side
chain of chlorophyll. As chlorophyll-bound phytol cannot
be metabolized by humans, and free phytol is present only
in minimal quantities in food, the phytanic acid present in
the human body is mostly provided by external sources

(Fig. 1). Ruminants ingest large amounts of chlorophyll,
from which phytol is efficiently cleaved off by bacteria in the
gastrointestinal tract. Phytol is subsequently taken up and
converted to phytanic acid, which is deposited in fat tissues
and in milk, the major sources of phytanic acid for humans
[2].
Accumulation of phytanic acid is typically seen in Adult
Refsum Disease (ARD) and is due to a deficient degrada-
tion of this exogenous 3-methyl-branched fatty acid [2,3].
Elevated phytanic acid levels can also be seen in peroxisome
biogenesis disorders, in which a defective a-oxidation is only
one of the deficiencies present [4]. Degradation of phytanic
acid via x-oxidation, by which a carboxylic acid group is
introduced at the omega end, has also been described [5,6],
but appears to be quantitatively less important under
physiological conditions. Its importance increases when
phytanic acid levels in serum are elevated as is seen in ARD
[7].
The degradation of phytanic acid via a-oxidation is
presently proposed to evolve completely in peroxisomes,
some doubts remaining, however, concerning the first
(activation) and last (aldehyde dehydrogenation) enzymatic
steps.
Degradation of 3-methyl-branched fatty acids
The classic catabolic pathway by which fatty acids are
degraded is b-oxidation and a mitochondrial as well as a
peroxisomal b-oxidation pathway is known [8]. Very long
chain fatty acids, 2-methyl-branched fatty acids, the side
chains of bile acid intermediates and eicosanoids are mainly/
exclusively handled by the peroxisomal pathway, whereas

short and medium chain fatty acids are oxidized mainly in
mitochondria [8].
Phytanic acid and other 3-methyl-branched fatty acids
cannot undergo b-oxidation because the 3-methyl-group
prevents the formation of a 3-keto substituent in the
dehydrogenation step. Therefore, 3-methyl-branched fatty
acids first undergo a-oxidation. In the case of phytanic acid,
this results in the generation of 2-methyl-branched pristanic
acid (2,6,10,14-tetramethylpentadecanoic acid), which is
then shortened to 4,8-dimethylnonanoic acid via peroxi-
somal b-oxidation. The dimethyl fatty acid is then degraded
further via mitochondrial b-oxidation.
Peroxisomes, in which most or all steps of the a-oxidation
pathway evolve, are subcellular organelles involved in a
number of anabolic (e.g. plasmalogen synthesis) and
catabolic processes, including a-andb-oxidation [8].
Peroxisomal enzymes are synthesized on polyribosomes in
the cytosol and are post-translationally imported into the
peroxisome. Therefore, these enzymes contain a series of
conserved amino acids or so called peroxisome targeting
signals (PTSs) [9]. Two classes of these topogenic sequences
Correspondence to M. Casteels, Afdeling Farmacologie, Department
of Molecular Cell Biology, Katholieke Universiteit Leuven,
Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium.
Fax: + 32 16 345699, Tel.: + 32 16 345816,
E-mail:
Abbreviations: PAHX, phytanoyl-CoA hydroxylase; 2-HPCL,
2-hydroxyphytanoyl-CoA lyase; ARD, Adult Refsum Disease;
PTS, peroxisome targeting signal; TPP, thiamine pyrophosphate.
(Received 15 November 2002, revised 15 February 2003,

accepted 21 February 2003)
Eur. J. Biochem. 270, 1619–1627 (2003) Ó FEBS 2003 doi:10.1046/j.1432-1033.2003.03534.x
have been described: PTS1, a carboxy-terminal tripeptide,
and PTS2, an amino-terminal nonapeptide [9]. A defect in
the PTS-receptors or other components of the import
machinery results in a generalized peroxisome biogenesis
disorder [4].
a-Oxidation of 3-methyl-branched fatty acids has already
been studied in the sixties and seventies, but only in the last
decade have most aspects of a-oxidation been unravelled [8].
For the study of this pathway both the natural substrate
phytanic acid, racemic at carbon 3, and the synthetic
(3-R,S)-methylhexadecanoic and (3-R,S)-methylheptadeca-
noic acids, have been used. It has been shown that the
synthetic 3-methyl-branched fatty acids are metabolized in
the same way as phytanic acid [10], and can validly be used
as substitutes for the latter substrate when studying
a-oxidation. A major breakthrough in a-oxidation research
was Poulos’ finding that in fibroblasts a-oxidation of
3-methyl-branched fatty acids generates not only CO
2
,as
was generally believed, but also formate [11]. Up till then
only CO
2
had been measured as an end product, and major
discrepancies existed between oxidation rates obtained in
intact cells (isolated hepatocytes, confluent fibroblasts),
permeabilized hepatocytes and broken cell systems (liver
homogenates, subcellular fractions) [8]. Subsequent meas-

urements of formate (plus formyl-CoA, see below) and CO
2
resolved the discrepancies between intact and permeabi-
lized/broken systems and allowed for the dissection of the
a-oxidation process. Our present knowledge of the enzy-
matic sequence is shown in Fig. 2.
In a first step the 3-methyl-branched fatty acid is activated
to the corresponding CoA-ester by an acyl-CoA synthetase
which is most probably present in the peroxisomal
membrane. It is not yet clear which synthetase is responsible
for the activation step: a nonspecific long chain fatty acyl-
CoA synthetase [12], a specific phytanoyl-CoA synthetase
[13] or a very long chain fatty acyl-CoA synthetase [14].
The second step is responsible for the iron dependence of
the pathway [15], which had been described by several
authors in the past but was regarded as doubtful concerning
its physiological relevance [16,17]. In this step the
3-methylacyl-CoA is hydroxylated in position 2 by a
dioxygenase, which is dependent on molecular O
2
, iron,
2-oxoglutarate, ascorbate, ATP/GTP and Mg
2+
[18–21].
This dioxygenase, named phytanoyl-CoA hydroxylase
(PAHX), contains a PTS2-signal and is present in the
peroxisomal matrix [22,23]. The product of the reaction
Fig. 1. Chemical structures of chlorophyll, phytol and phytanic acid
(3,7,11,15-tetramethylhexadecanoic acid).
Fig. 2. a-Oxidation of 3-methyl-branched fatty acids. The scheme

represents the a-oxidation pathway of phytanic acid. The numbers
indicate the enzymes catalysing the different steps: (1) acyl-CoA syn-
thetase; (2) phytanoyl-CoA hydroxylase (PAHX); (3) 2-hydroxy-
phytanoyl-CoA lyase (2-HPCL); (4) aldehyde dehydrogenase; and (5)
formyl-CoA hydrolase.
1620 M. Casteels et al. (Eur. J. Biochem. 270) Ó FEBS 2003
catalysed by PAHX is a 2-hydroxy-3-methylacyl-CoA, or, if
phytanic acid is the substrate, 2-hydroxyphytanoyl-CoA.
The PAHX gene is located on chromosome 10 [22], and
mutations of this gene are probably the most frequent cause
of ARD [22–25]. Structure-function analysis of PAHX
further revealed that at least four different types of
mutations can cause loss of enzyme activity [25].
In the third step, 2-hydroxy-3-methylacyl-CoA is cleaved
in the peroxisomal matrix [26,27] by 2-hydroxyphytanoyl-
CoA lyase (2-HPCL), which uses thiamine pyrophosphate
(TPP) as cofactor [26]. Products of this reaction are formyl-
CoA [28] and a 2-methyl-branched fatty aldehyde (pristanal
when 2-hydroxyphytanoyl-CoA is cleaved) [29,30], both of
which had been identified before the discovery of the lyase
(see below).
The 2-methyl-branched fatty aldehyde is subsequently
dehydrogenated by an NAD
+
-dependent aldehyde dehy-
drogenase to a 2-methyl-branched fatty acid (pristanic acid
in the case of pristanal), which can be activated to the
corresponding acyl-CoA ester. This CoA-ester can then
enter the peroxisomal b-oxidation sequence. The 2-methyl
aldehyde dehydrogenase activity is located in the peroxi-

somal matrix according to Croes et al.[29]andinthe
endoplasmic reticulum (microsomes) according to Verho-
even et al. [30]. It remains at present unclear which aldehyde
dehydrogenase is involved. Measurements in Sjo
¨
gren–
Larsson syndrome (SLS) fibroblasts, the microsomal alde-
hyde dehydrogenase of which is deficient, show only a 30%
decrease in dehydrogenation rates of pristanal [31,32] and
make an exclusive role of a microsomal aldehyde dehy-
drogenase unlikely.
The major part of formyl-CoA is enzymatically converted
to formate in peroxisomes [28]. It was shown previously [33]
that in rats, aminotriazole, known as an inhibitor of
catalase, had little effect on the conversion of
14
C-formate to
CO
2
(but decreased the rates of a-oxidation by 90%). In rat
formate is metabolized by two pathways: the catalase
pathway and the tetrahydrofolate pathway, important in
one carbon-metabolism [34]. The data on aminotriazole
indicate that at least in the rat the catalase pathway is of no
paramount importance, and suggest that the tetrahydro-
folate pathway is quantitatively more important for formate
metabolism [33]. We studied the conversion of
14
C-formate
to

14
CO
2
in rat and found it to be localized mainly in the
cytosolic fraction, and to be stimulated by NAD
+
[19]. No
further work on the fate of formate as a product of
a-oxidation has been published since. Nothing is known
on the export of formate from the peroxisome, but it is
supposed that formate, as well as other small organic acids
can leak from the peroxisomes [35].
Table 1 gives an overview of the presently known
characteristics of the four main enzymes of the a-oxidation
pathway.
Stereospecificity of the a-oxidation pathway
Phytol has two chiral centres, one at carbon 7 and one at
carbon 11, both of which are of the R-configuration [41].
Non-specific reduction of the double bond in phytol leads
to the production of two diastereoisomers: (3S,7R,11R)-
and (3R,7R,11R)-phytanic acid [42]. Phytanic acid
from all common sources is a mixture of these two
Table 1. Properties of the enzymatic steps/enzymes of the a-oxidation pathway. The table gives an overview of the present knowledge of some of the
properties of the enzymes involved in the initial degradation of 3-methyl-branched fatty acids in humans. See text for details.
Acyl-CoA
synthetase
Phytanoyl-CoA hydroxylase
(PAHX)
2-Hydroxyphytanoyl-CoA lyase
(2-HPCL)

Aldehyde
dehydrogenase
Accession number O14832 Q9UJ83
Gene mapping 10p15.1 [22] 3p25 [39]
Mass of subunit Unprocessed: 38 556/
mature: 35 436 Da
Monomer: 63 732 Da
Cofactors ATP, CoA, Mg
2+
O
2
,Fe
2+
, ascorbate, 2-oxoglutarate
[18,19]
TPP, Mg
2+
[26] NAD
+
[29,30]
ATP/GTP, Mg
2+
[21]
K
m
for CoA-ester 29.5 ± 1.7 lM
b
[36] 15 lM
d
[26]

Subcellular localization Peroxisomal
membrane [12–14]?
Peroxisomal matrix [19,20] Peroxisomal matrix [26,27] Peroxisomes
[29,32]?
Targeting PTS-2 [22,23] PTS-1 [26]
Stereochemistry Not stereospecific
a
3Rfi2S,3R;3Sfi2R,3S
c
[37,38] Not stereospecific [38] Unknown
e
Heterologous expression
systems
E. coli Mammalian cells,
S. cerevisiae [26,39]
Mutagenesis studies Yes [22,24,25] No
Structural information Yes [25] TPP binding domain [26,39]
a
As both phytanic acid and phytanoyl-CoA are racemic at position 3, it is supposed that the acyl-CoA synthetase is not stereospecific.
Whether the activation rates for the R- and S-isomers are different, as shown for the conversion of 2-methyl-branched fatty acids to the
corresponding acyl-CoA esters in human liver [40], is not known.
b
K
m
determined for phytanoyl-CoA with recombinant PAHX, in the
presence of equimolar concentrations of SCP-2.
c
Phytanoyl-CoA hydroxylase is not stereospecific, but the configuration of the methyl-
branch at position 3 determines the orientation of the hydroxy-group at position 2. Eventually, only (2R,3S) and (2S,3R) isomers are
formed.

d
K
m
determined for 2-hydroxy-3-methyl-C16-CoA with partially purified enzyme.
e
Although nothing is known about the stereo-
specificity of aldehyde dehydrogenases, it can be postulated from all different data concerning the stereochemistry of the a-oxidation
pathway that this last step of the reaction sequence is not stereospecific.
Ó FEBS 2003 Alpha-oxidation and its TPP dependence (Eur. J. Biochem. 270) 1621
diastereoisomers and their ratios are variable and depend-
ent on sample origin. As the a-oxidation product of
racemic phytanic acid, pristanic acid, is racemic at
position 2, it seems obvious that both stereoisomers can
undergo a-oxidation without a previous isomerization at
the initial 3-methyl-branch. Croes et al.[38]provided
indeed evidence that isomerization of the 3-methyl-branch
during a-oxidation does not occur and that the configur-
ation of the methyl-branch is conserved throughout the
whole a-oxidation process. It was also demonstrated that
the configuration of the 3-methyl-branch does not influ-
ence the rate of a-oxidation, but determines the orienta-
tion of the 2-hydroxylation. This explains the formation
of only the (2S,3R)and(2R,3S) isomers of 2-hydroxy-3-
methylhexadecanoyl-CoA by purified peroxisomes, despite
the experimental finding that all four possible isomers
(although each to a different extent) can be metabolized
[38]. The data of Croes et al. confirm the earlier findings
of Tsai [37], who concluded that the introduction of the
hydroxy group at position 2 is stereospecific and deter-
mined by the configuration of the methyl group at

position 3. The stereochemistry of the a-oxidation path-
way is presented in Fig. 3.
The lack of stereospecificity of the a-oxidation pathway is
in contrast with the stereospecificity of both the peroxisomal
and mitochondrial b-oxidation systems. As a-oxidation of
phytanic acid results in both stereoisomers of pristanic acid,
the produced (2R,6R,10R) isomer has to undergo racemi-
zation at carbon 2 before b-oxidation can take place. In
addition, racemization at the other chiral centres is an
essential step for the further b-oxidation of the intermediate
a-methyl fatty acids [40].
2-HPCL: a thiamine dependent enzyme
2-HPCL identification
After the discovery by Poulos et al. [11] of formate as a
product of a-oxidation in fibroblasts, a finding which was
confirmed in isolated hepatocytes [33], Croes et al. found in
1997 that not formate (or CO
2
) was the primary end
product but formyl-CoA [28]. This finding led several
authors to propose a reaction mechanism in which the
other product would be a 2-methyl-branched aldehyde
(or pristanal in case phytanic acid is the substrate). Soon,
the formation of a 2-methyl-branched aldehyde, using
2-hydroxy-3-methylacyl-CoA or 2-hydroxyphytanoyl-CoA
as precursor, was demonstrated simultaneously by Croes
et al. [29] and Verhoeven et al.[30].
Foulon et al. used 2-hydroxy-3-methylhexadecanoyl-
CoA as substrate for studying the third reaction of the
a-oxidation pathway, and measured formate (together with

formyl-CoA, which is, partly enzymatically, converted to
formate) as the reaction product [26].
Subcellular fractionation studies in rat liver demonstra-
ted that the lyase activity colocalized with catalase in the
peroxisomal fraction [26]. Hence, isolation of the pre-
sumptive cleavage enzyme was started from the matrix
protein fraction of isolated rat liver peroxisomes. The
purified lyase was made up of four identical subunits of
63 kDa. Formyl-CoA and 2-methylpentadecanal (meas-
ured by GC-analysis) were identified as reaction products
when the enzyme (in the presence of thiamine pyrophos-
phate (TPP), see below) was incubated with 2-hydroxy-
3-methylhexadecanoyl-CoA as the substrate. Quantitative
measurements of both reaction products further confirmed
the stoichiometry of the cleavage step. Incubations in the
presence of NAD
+
(a cofactor for fatty aldehyde
dehydrogenation [43]) did not alter the amount of formate
(formyl-CoA) and 2-methyl-pentadecanal formed, and no
conversion of the aldehyde to a fatty acid could be
demonstrated indicating that this reaction is performed by
a separate enzyme. Hence, as the only activity of the
purified enzyme is the specific cleavage of a carbon-carbon
bond, it was called 2-hydroxyphytanoyl-CoA lyase or
2-HPCL [26].
An apparent Km of 15 l
M
for 2-hydroxy-3-methylhexa-
decanoyl-CoA was calculated. The pH optimum was

between 7.5 and 8.0 [26].
TPP-dependence of 2-HPCL
Originally, 2-HPCL had been purified in the absence of TPP
and the enzyme lost virtually all of its activity during
purification. The amino-acid sequences of tryptic peptides
from the purified and barely active 2-HPCL suggested that
the cleavage enzyme is related to a putative Caenorhabditis
elegans protein that displays homology to bacterial oxalyl-
CoA decarboxylases [44,45]. These enzymes, which have
hitherto only been described in bacteria, catalyse the TPP-
dependent decarboxylation of oxalyl-CoA to formyl-CoA
Fig. 3. Stereochemistry of the a-oxidation pathway. The scheme rep-
resents the a-oxidation pathway of (3R,3S)-methylhexadecanoic acid
and the stereochemical configuration of the intermediates involved.
The numbers indicate the enzymes catalysing the different steps: (1)
acyl-CoA synthetase; (2) phytanoyl-CoA hydroxylase (PAHX); (3)
2-hydroxyphytanoyl-CoA lyase (2-HPCL); (4) aldehyde dehydro-
genase; (5) formyl-CoA hydrolase; (6) acyl-CoA synthetase; and (7)
2-methylacyl-CoA racemase, responsible for the conversion of the
2R-methylacyl-CoA into the 2S-methylacyl-CoA, as only the S-isomer
can undergo b-oxidation.
1622 M. Casteels et al. (Eur. J. Biochem. 270) Ó FEBS 2003
and CO
2
[44,45]. This homology suggested that also
2-HPCL might require TPP, an unexpected cofactor for
a-oxidation.
In the presence of 0.8 m
M
Mg

2+
, optimum activity for
the purified enzyme was reached at 20 l
M
TPP (K
m
for
TPP ¼ 8.43 l
M
). Only minor stimulation by TPP was
noted in a fresh liver homogenate (1.3 fold), and a gradually
more potent stimulation of the lyase activity was observed
as the enzyme became more purified. Hence, optimal lyase
measurements have to be performed in the presence of TPP
and MgCl
2
.
cDNA and amino-acid sequence
The cDNA sequence of the human lyase contains an open
reading frame of 1734 nucleotides encoding a polypeptide
with a calculated molecular mass of 63 732 Da. Similarly
to other TPP-dependent enzymes (e.g. bacterial oxalyl-
CoA decarboxylases), a TPP-binding consensus domain
could be identified in the C-terminal part of the lyase. The
corresponding peptide sequences of this domain in the
human, mouse and rat enzyme, comply exactly with
the TPP consensus domain of pyruvate decarboxylase of
Saccharomyces cerevisiae, acetolactate synthase of Escheri-
chia coli, oxalyl-CoA decarboxylase of Oxalobacter formi-
genes and the putative oxalyl-CoA decarboxylases of

Caenorhabditis elegans and S. cerevisiae [44,45] (Fig. 4
[46]).
Substrate specificity of 2-HPCL
Recombinant human protein, expressed in mammalian cells
or in a yeast system, clearly exhibited lyase activity, whereas
expression in a bacterial system did not result in a
functionally active enzyme [26].
Study of the substrate specificity of recombinant
human lyase revealed that the enzyme is not only active
towards 2-hydroxy-3-methylhexadecanoyl-CoA (the
analogue of 2-hydroxyphytanoyl-CoA), but also,
although to a minor extent, towards 2-hydroxyoctadeca-
noyl-CoA (± 12% of control activity) at equal substrate
concentration. The latter compound, however, as well as
2-hydroxyhexadecanoyl-CoA, effected a very strong inhi-
bition on the cleavage of 2-hydroxy-3-methylhexadeca-
noyl-CoA, most probably due to competition [39]. No
activity at all was seen with 2-hydroxy-3-methylhexadeca-
noic acid, 3-methylhexadecanoic acid or 3-methylhexa-
decanoyl-CoA, indicating that both a 2-hydroxy group
and a CoA-moiety, but not a 3-methyl-branch, are
necessary for lyase activity [39].
Identification of novel PTS
At first glance, the Hs 2-HPCL sequence did not contain a
C-terminal or N-terminal peroxisome targeting signal
(PTS). As the C. elegans orthologue ends in a putative
PTS1 (SKM) and as PRL, the C-terminal tripeptide of the
S. cerevisiae orthologue, had been shown to bind to the
human PTS1 import receptor [47], the C-terminal sequence
SNM, which is also conserved in the mouse counterpart,

was considered to have a targeting function. Transfection
studies with constructs coding for 2-HPCL fused to GFP
revealed that the fluorescence localized to peroxisomes in
fibroblasts from PEX5
+/–
miceandtothecytosolin
fibroblasts from PEX5
–/–
mice [26]. The latter mice lack the
PTS1 receptor (Pex5p) and do not import PTS1-containing
proteins into their peroxisomes [48]. As a GFP-construct
containing only the last 5 amino acids of 2-HPCL localized
to peroxisomes in fibroblasts from normal mice, we can
conclude that targeting information is present within this
pentapeptide and that SNM, preceded by a positive charge,
is a hitherto unrecognized PTS1 [26].
Reaction mechanism of 2-HPCL
A 2-hydroxy carboxyl compound (instead of a 2-keto
carboxyl compound) is a rather unusual substrate for
thiamine dependent decarboxylases. In all TPP-dependent
reactions described so far, catalysis involves activation of
the C2-H of the thiazole ring, followed by a nucleophilic
attack at the carbonyl carbon of the substrate [49]. By use of
nuclear magnetic resonance spectroscopy, it has been shown
that in the enzyme-bound state, the C2 proton of TPP is
undissociated, but that the protein component dramatically
accelerates the deprotonation, producing an intermediate
C2 carbanion with a short lifetime [50,51]. Most likely, the
formation of a carbanion is also required for the cleavage of
2-hydroxy-3-methylacyl-CoAs by 2-HPCL (Fig. 5). How-

ever, this carbanion will attack carbon 1 of the substrate,
which is highly reactive due to the nature of the thioester
bond. Ultimately this leads to the formation of formyl-CoA
and a 2-methyl-branched fatty aldehyde.
Fig. 4. Alignment of the cofactor-binding consensus domain in TPP-dependent enzymes. An alignment [26] is given of the cofactor-binding consensus
domain in several TPP-dependent enzymes (Sc PDC: S. cerevisiae pyruvate decarboxylase; Ec ALS: E. coli acetolactate synthase; Of OCD:
O. formigenes oxalyl-CoA decarboxylase) and in Hs 2-HPCL and its homologues in lower organisms (Ce OCD: C. elegans putative oxalyl-CoA
decarboxylase; Sc OCD: S. cerevisiae putative oxalyl-CoA decarboxylase). The TPP-binding consensus motif, here represented with 10 residues
upstream and downstream, is defined as G-D-G-x-(24–27)-N-N [46]. About 10 residues downstream of the G-D-G sequence, a negatively charged
amino acid is present (E or D), followed about 5 and 11 residues further by a generally conserved alanine and proline residue, respectively.
Immediately preceding the N-N sequence is a cluster of 6 or 7 largely hydrophobic side-chains.
Ó FEBS 2003 Alpha-oxidation and its TPP dependence (Eur. J. Biochem. 270) 1623
As 2-hydroxy-acyl-CoA esters seem to be unusual
substrates for TPP-dependent enzymes, Jones et al.[52]
proposed another mechanism for a-oxidation from the
conversion of 2-hydroxyphytanoyl-CoA onwards. This
would involve hydrolysis of the CoA-ester (peroxisomal
thioesterases have been described [53]) and a subsequent
oxidation generating 2-ketophytanic acid, which would
then be cleaved by 2-HPCL, the enzyme described by us
[26]. This hypothesis would turn 2-HPCL into a not so
unusual TPP-dependent enzyme as its substrate would
then be a 2-keto-compound. However, the activity of
the required thioesterases toward the proposed substrate
has never been demonstrated and the 2-hydroxyacid
oxidase, present in kidney, is only active on
L-2-hydroxyphytanic acid [54], whereas the activity of
2-HPCL vs. 2-hydroxy-3-methylacyl-CoA has unequivo-
cally been proven. Moreover, if, according to the
hypothesis of Jones et al. [52], a thioesterase and a

2-hydroxyacid oxidase would be involved, no formyl-
CoA/formate would be produced. This would be in
contrast with the solid findings of several authors
[11,18,19,28,33,55].
Mapping of the 2-HPCL gene
The human 2-HPCL gene has been mapped to chromo-
some 3p25 (Foulon V., Vermeesch J., Mannaerts G.P.,
Casteels M., Van Veldhoven P.P.; unpublished results).
The complete Hs 2-HPCL gene spans 40.8 kb and contains
17 exons, with intron sizes ranging from 190 bp to 4700 bp.
All exon-intron boundaries are conform to the consensus
rules [56], ending in an AG doublet and starting with a GT
pair.
Gene defects of 2-HPCL associated
with ARD?
Although several diseases are known to be associated with
3p25, none of these appear to be linked to 2-HPCL.
Moreover, up till now no patients with a deficient 2-HPCL,
which would probably result in a clinical picture similar to
ARD, have been identified. The mapping of the 2-HPCL
gene is a first step towards the finding and diagnosis of such
patients.
Deficient breakdown of phytanic acid
Elevated serum levels of phytanic acid are typical for
patients with an isolated defective a-oxidation but can also
be seen in patients with peroxisome biogenesis disorders.
In the latter patients the accumulation of phytanic acid is
only one of the features present [4].
The most typical clinical picture of an isolated defect in
phytanic acid breakdown is described as ARD [2,3]. The

gradual accumulation of phytanic acid in serum and tissues
of these patients results only in the second or third decade in
distinct symptoms. Virtually all patients show retinitis
pigmentosa, night blindness and anosmia (deficient smelling
sensation; 80% of ARD patients). In addition, polyneuro-
pathy (60%), deafness (60%), ataxia (50%) and ichtyosis
(20%) are quite common (for a review, see Wierzbicki et al.
[3]). A prerequisite for the diagnosis of ARD is the presence
of an elevated serum level of phytanic acid (above 200 l
M
whereas normal phytanic acid levels in serum are below
30 l
M
). However, there seems to be no strict correlation
between the level of phytanic acid accumulation and the
severity of the clinical symptoms. Interestingly, 30–40%
of the patients are born with an absence of one of the
metacarpals or metatarsals (bone in the hand or forefoot,
respectively).
The pathophysiology and the cause of the retinal and
specific neurological manifestations of ARD remain at
present unknown. Feeding control animals excessive
amounts of phytol can lead to similar severe neurological
symptoms as in ARD, indicating that at least some of the
symptoms in ARD might be directly related to an accumu-
lation of phytanic acid. Most obviously, the study of animal
models for ARD will help to clarify the pathogenetic
mechanisms of this disease.
The clinical spectrum of ARD can be ascribed to different
molecular and genetic defects [57]. Probably most frequent

isadefectatthelevelofPAHX, mapped to chromosome
10p15.1 [22,23]. However, some patients show a low or
absent phytanoyl-CoA hydroxylase activity, but no muta-
tion in PAHX. Van den Brink et al. [58] described in 2 such
Fig. 5. Generation of a carbanion in enzyme-bound TPP and proposed
reaction mechanism for 2-HPCL. In order to react with the substrate,
the C2-H of TPP must be activated by the protein component. A key
function for this activation is the interaction of a conserved glutamate
[50,51] with the N1¢ atom of the coenzyme, resulting in an increased
basicity of its 4¢ amino group, facilitating the deprotonation of the C2.
1624 M. Casteels et al. (Eur. J. Biochem. 270) Ó FEBS 2003
patients, who had been clinically diagnosed as ARD, a
mutation in the gene encoding PEX7p, the PTS2 import
receptor, apparently resulting in a deficient peroxisomal
import of the PTS2 containing PAHX. These patients had
normal peroxisomes, normal peroxisomal b-oxidation, no
or very low PAHX activity, and deficient plasmalogen
synthesis, which is also dependent on an intact import of
PTS2 containing proteins. So far, PEX7 mutations were
known to cause rhizomelic chondrodysplasia punctata
(RCDP), resulting in a short lifespan [59–61], but they can
apparently also result in a much milder phenotype with late
onset. Additionally, Ferdinandusse et al. described two
atypical ÔARDÕ patients, who eventually appeared to have a
racemase deficiency [62] (see legend to Fig. 3). Nevertheless,
in some patients with the clinical syndrome of ARD none of
these specific molecular defects could be found and the
genetic basis of the disease in these patients awaits to be
defined.
Conclusions and perspectives

2-HPCL is the first mammalian peroxisomal enzyme that is
TPP dependent. This finding raises several questions
discussed below.
(a) The TPP dependence of 2-HPCL renders the
a-oxidation pathway thiamine dependent as a whole. This
could imply that the thiamine status of the cell would
influence the a-oxidation process, but so far no indication
pointing to this hypothesis can be found in the literature.
Preliminary experiments with cultured C6-glia cells or
control human fibroblasts in thiamine-deficient conditions
(generated either by the addition of oxythiamine to the
growth medium, or by culturing cells in thiamine-depleted
medium) showed a decrease of the overall flux through
the a-oxidation pathway (V. Foulon, M. Casteels &
P.P. Van Veldhoven, unpublished results). Whether
overall a-oxidation would be deficient in patients with
thiamine deficiency as, e.g. thiamine responsive megalo-
blastic anemia (TRMA), and whether this would lead to an
accumulation of phytanic acid in these patients, remains to
be investigated.
(b) A TPP dependent reaction in peroxisomes requires
the presence of thiamine or thiamine pyrophosphate
inside the peroxisome. It was shown recently that the
thiamine transporter SLC19A2, which is deficient in
TRMA, is not only present on the plasma membrane
but also on the mitochondrial membrane [63]. No report
was made however, on the presence of this transporter
(or one of his homologues) on the peroxisomal mem-
brane. As 2-HPCL is the first mammalian peroxisomal
enzyme described to be TPP-dependent, the mechanism

for the import of thiamine/TPP into peroxisomes remains
to be explored.
Acknowledgements
This work was supported by grants from the ÔGeconcerteerde
onderzoeksacties van de Vlaamse GemeenschapÕ (GOA 94/98–12 and
GOA 99/03–09) and from the ÔFonds voor Wetenschappelijk Onder-
zoek-VlaanderenÕ (G-0239.98, G.0164.96 N and G.0115.02). V.F. was
supported by a fellowship from the ÔFonds voor Wetenschappelijk
Onderzoek-VlaanderenÕ.
References
1. Klenk, E. & Kahlke, W. (1963) U
¨
ber das Vorkommen der
3,7,11,15-Tetramethylhexadecansa
¨
ure (Phytansa
¨
ure) in den Cho-
lesterinestern und andere Lipidfractionen der Organe bei einem
Krankheitsfall unbekannter Genese (Verdacht auf Heredopathia
Atactica Polyneuritiformis [Refsum Syndrome]). Hoppe Zeilers Z.
Physiol. Chem. 333, 133–139.
2. Steinberg, D. (1995) Refsum disease. In The Metabolic and
Molecular Bases of Inherited Disease (C.R. Scriver, A.L. Beaudet,
W.S. Sly & D. Valle, eds.), 7th edn, pp. 2351–2369. McGraw-Hill,
New York.
3. Wierzbicki, A.S., Lloyd, M.D., Schofield, C.J., Feher, M.D. &
Gibberd, F.B. (2002) Refsum’s disease: a peroxisomal disorder
affecting phytanic acid a-oxidation. J. Neurochem. 80, 727–735.
4. Brosius, U. & Ga

¨
rtner, J. (2002) Cellular and molecular aspects of
Zellweger syndrome and other peroxisome biogenesis disorders.
Cell. Mol. Life Sci. 59, 1058–1069.
5. Brenton, D.P. & Krywawych, S. (1982) 3-Methyladipate excretion
in Refsum’s disease. Lancet 1, 624.
6. Try, K. (1968) The in vitro omega-oxidation of phytanic acid and
other branched chain fatty acids by mammalian liver. Scand.
J. Laboratory Invest. 22, 224–230.
7. Wierzbicki, A.S., Mayne, P.D., Lloyd, M.D., Burston, D.,
Mei, G., Sidey, M.C., Feher, M.D. & Gibberd, F.B. (2002)
Metabolism of phytanic acid and 3-methyl-adipic acids in patients
with Adult Refsum’s disease. In Peroxisomal Disorders and
Regulation of Genes, 25–28 September 2002, Belgian Society for
Cell and Developmental Biology, Ghent, Belgium.
8. Mannaerts, G.P., Van Veldhoven, P.P. & Casteels, M. (2000)
Peroxisomal lipid degradation via a-andb-oxidation in mammals.
Cell Biochem. Biophysics 32, 73–87.
9. Terlecky, S.R. & Fransen, M. (2000) How peroxisomes arise.
Traffic 1, 465–473.
10. Van Veldhoven, P.P., Huang, S., Eyssen, H.J. & Mannaerts, G.P.
(1993) The deficient degradation of synthetic 2- and 3-methyl-
branched fatty acids in fibroblasts from patients with peroxisomal
disorders. J. Inher. Metab. Dis. 16, 381–391.
11. Poulos, A., Sharp, P., Singh, H., Johnson, D.W., Carey, W.F. &
Easton, C. (1993) Formic acid is a product of the a-oxidation of
fatty acids by human skin fibroblasts: deficiency of formic acid
production in peroxisome-deficient fibroblasts. Biochem. J. 292,
457–461.
12. Watkins, P.A., Howard, A.E., Gould, S.J., Avigan, J. & Mihalik,

S.J. (1996) Phytanic acid activation in rat liver peroxisomes is
catalyzed by long-chain acyl-CoA synthetase. J. Lipid Res. 37,
2288–2295.
13. Pahan, K., Cofer, K., Baliga, P. & Singh, I. (1993) Identification
of phytanoyl-CoA ligase as a distinct acyl-CoA ligase in peroxi-
somes from cultured human skin fibroblasts. FEBS Lett. 322,101–
104.
14. Steinberg, S.J., Wang, S.J., Kim, D.G., Mihalik, S.J. & Watkins,
P.A. (1999) Human very-long-chain acyl-CoA synthetase: cloning,
topography, and relevance to branched-chain fatty acid metabo-
lism. Biochem. Biophys. Res. Commun. 257, 615–621.
15. Croes, K., Casteels, M., Van Veldhoven, P.P. & Mannaerts, G.P.
(1995) Evidence for the importance of iron in the alpha-oxidation
of 3-methyl-substituted fatty acids in the intact cell. Biochimica
Biophysica Acta 1255, 63–67.
16. Tsai, S.C., Avigan, J. & Steinberg, D. (1969) Studies on the alpha-
oxidation of phytanic acid by rat liver mitochondria. J. Biol.
Chem. 244, 2682–2692.
17. Huang, S., Van Veldhoven, P.P., Vanhoutte, F., Parmentier, G.,
Eyssen,H.J.&Mannaerts,G.P.(1992)a-Oxidation of 3-methyl-
substituted fatty acids in rat liver. Arch. Biochem. Biophys. 296,
214–223.
Ó FEBS 2003 Alpha-oxidation and its TPP dependence (Eur. J. Biochem. 270) 1625
18. Mihalik, S.J., Rainville, A.M. & Watkins, P.A. (1995) Phytanic
acid a-oxidaton in rat liver peroxisomes. Production of
a-hydroxyphytanoyl-CoA and formate is enhanced by dioxyge-
nase cofactors. Eur. J. Biochem. 232, 545–551.
19. Croes, K., Casteels, M., Mannaerts, G.P. & Van Veldhoven, P.P.
(1996) a-Oxidation of 3-methyl-substituted fatty acids in rat liver.
Production of formic acid instead of CO

2
, cofactor requirements,
subcellular localization and formation of a 2-hydroxy-3-methyl-
acyl-CoA intermediate. Eur. J. Biochem. 240, 674–683.
20. Jansen, G.A., Mihalik, S.J., Watkins, P.A., Moser, H.W., Jakobs,
C., Denis, S. & Wanders, R.J.A. (1996) Phytanoyl-CoA hydro-
xylase is present in human liver, located in peroxisomes, and
deficient in Zellweger syndrome: direct, unequivocal evidence for
the new, revised pathway of phytanic acid a-oxidation in humans.
Biochem. Biophys. Res. Commun. 229, 205–210.
21. Croes, K., Foulon, V., Casteels, M., Van Veldhoven, P.P. &
Mannaerts, G.P. (2000) Phytanoyl-CoA hydroxylase: recognition
of 3-methyl-branched acyl-CoAs and requirement for GTP or
ATP and Mg
2+
in addition to its known hydroxylation cofactors.
J. Lipid Res. 41, 629–636.
22. Mihalik, S.J., Morrell, J.C., Kim, D., Sacksteder, K.A., Watkins,
P.A. & Gould, S.J. (1997) Identification of PAHX, a Refsum
disease gene. Nat. Genet. 17, 185–189.
23. Jansen, G.A., Ofman, R., Ferdinandusse, S., Ijlst, L., Muijsers,
A.O., Skjeldal, O.H., Stokke, O., Jakobs, C., Besley, G.T.N.,
Wraith, J.E. & Wanders, R.J.A. (1997) Refsum disease is caused
by mutations in the phytanoyl-CoA hydroxylase gene. Nat. Genet.
17, 190–193.
24. Jansen, G.A., Hogenhout, E.M., Ferdinandusse, S., Waterham,
H.R., Ofman, R., Jakobs, C., Skjeldal, O.H. & Wanders, R.J.
(2000) Human phytanoyl-CoA hydroxylase: resolution of the gene
structure and the molecular basis of Refsum’s disease. Hum. Mol.
Genet. 9, 1195–1200.

25. Mukherji, M., Chien, W., Kershaw, N.J., Clifton, I.J., Schofield,
C.J., Wierzbicki, A.S. & Lloyd, M.D. (2001) Structure-function
analysis of phytanoyl-CoA 2-hydroxylase mutations causing
Refsum’s disease. Hum. Mol. Genet. 10, 1971–1982.
26. Foulon, V., Antonenkov, V.D., Croes, K., Waelkens, E.,
Mannaerts, G.P., Van Veldhoven, P.P. & Casteels, M. (1999)
Purification, molecular cloning, and expression of 2-hydroxy-
phytanoyl-CoA lyase, a peroxisomal thiamine pyrophosphate-
dependent enzyme that catalyzes the carbon-carbon bond cleavage
during alpha-oxidation of 3-methyl-branched fatty acids. Proc.
NatlAcad.Sci.USA96, 10039–10044.
27. Jansen,G.A.,Denis,S.,Verhoeven,N.M.,Jakobs,C.&Wanders,
R.J. (2000) Phytanic acid alpha-oxidation in man: identification of
2-hydroxyphytanoyl-CoA lyase, a peroxisomal enzyme with normal
activity in Zellweger syndrome. J. Inherit. Metab. Dis. 23, 421–424.
28. Croes,K.,VanVeldhoven,P.P.,Mannaerts,G.P.&Casteels,M.
(1997) Production of formyl-CoA during peroxisomal a-oxidation
of 3-methyl-branched fatty acids. FEBS Lett. 407, 197–200.
29. Croes,K.,Casteels,M.,Asselberghs,S.,Herdewijn,P.,Manna-
erts, G.P. & Van Veldhoven, P.P. (1997) Formation of a 2-methyl-
branched fatty aldehyde during peroxisomal a-oxidation. FEBS
Lett. 412, 643–645.
30. Verhoeven, N.M., Schor, D.S.M., ten Brink, H.J., Wanders,
R.J.A. & Jakobs, C. (1997) Resolution of the phytanic acid
a-oxidation pathway: identification of pristanal as product of the
decarboxylation of 2-hydroxyphytanoyl-CoA. Biochem. Biophys.
Res. Commun. 237, 33–36.
31. Verhoeven, N.M., Jakobs, C., Carney, G., Somers, M.P., Wan-
ders, R.J. & Rizzo, W.B. (1998) Involvement of microsomal fatty
aldehyde dehydrogenase in the alpha-oxidation of phytanic acid.

FEBS Lett. 429, 225–228.
32. Jansen,G.A.,vandenBrink,D.M.,Ofman,R.,Draghici,O.,
Dacremont, G. & Wanders, R.J. (2001) Identification of pristanal
dehydrogenase activity in peroxisomes: conclusive evidence that
the complete phytanic acid alpha-oxidation pathway is localized in
peroxisomes. Biochem. Biophys. Res. Commun. 283, 674–679.
33. Casteels, M., Croes, K., Van Veldhoven, P.P. & Mannaerts, G.P.
(1994) Aminotriazole is a potent inhibitor of a-oxidation of,
3-methyl-substituted fatty acids in rat liver. Biochem. Pharmacol.
48, 1973–1975.
34. Palese, M. & Tephly, T.R. (1975) Metabolism of formate in the
rat. J. Toxicol. Environ. Health 1, 13–24.
35. Igamberdiev, A.U. & Lea, P.J. (2002) The role of peroxisomes in
the integration of metabolism and evolutionary diversity of pho-
tosynthetic organisms. Phytochemistry 60, 651–674.
36. Mukherji, M., Kershaw, N.J., Schofield, C.J., Wierzbicki, A.S. &
Lloyd, M.D. (2002) Utilization of sterol carrier protein-2 by
phytanoyl-CoA hydroxylase in the peroxisomal a-oxidation of
phytanic acid. Chem. Biol. 9, 597–605.
37. Tsai, S.C., Steinberg, D., Avigan, J. & Fales, H.M. (1973) Studies
on the stereospecificity of mitochondrial oxidation of phytanic
acid and of a-hydroxyphytanic acid. J. Biol. Chem. 246, 1091–
1097.
38. Croes, K., Casteels, M., Dieuaide-Noubhani, M., Mannaerts,
G.P. & Van Veldhoven, P.P. (1999) Stereochemistry of the
a-oxidation of 3-methyl-branched fatty acids in rat liver. J. Lipid
Res. 40, 601–609.
39. Foulon, V. (2001) a-Oxidation of 3-Methyl-Branched Fatty Acids:
Study of the Enzymes Involved in the Reaction Sequence.PhD
Thesis. Leuven University Press, Leuven.

40. Schmitz, W. & Conzelmann, E. (1997) Stereochemistry of peroxi-
somal and mitochondrial b-oxidation of a-methyacyl-CoAs. Eur.
J. Biochem. 244, 434–440.
41. Burrell, J.W.K., Jackman, L.M. & Weedon, B.C.L. (1959)
Stereochemistry and synthesis of phytol, geraniol, and nerol.
Proceedings of the Chem. Soc. 263–264.
42. Ackman, R.G. & Hansen, R.P. (1967) The occurrence of dia-
stereoisomers of phytanic and pristanic acids and their determi-
nation by gas-liquid chromatography. Lipids 2, 357–362.
43. Antonenkov, V.D., Pirozhkov, S.J. & Panchenko, L.F. (1985)
Intraparticulate localization and some properties of a clofibrate-
induced peroxisomal aldehyde dehydrogenase from rat liver. Eur.
J. Biochem. 149, 159–167.
44. Baetz, A.L. & Allison, M.J. (1989) Purification and characteriza-
tion of oxalyl-coenzyme A decarboxylase from Oxalobacter for-
migenes. J. Bacteriol. 171, 2605–2608.
45. Lung, H.Y., Baetz, A.L. & Peck, A.B. (1994) Molecular cloning,
DNA sequence, and gene expression of the oxalyl-coenzyme A
decarboxylase gene, oxc, from the bacterium Oxalobacter for-
migenes. J. Bacteriol. 176, 2468–2472.
46. Hawkins, C.F., Borges, A. & Perham, R.N. (1989) A common
structural motif in thiamin pyrophosphate-binding enzymes.
FEBS Lett. 255, 77–82.
47. Lametschwandtner, G., Brocard, C., Fransen, M., Van Veldhoven,
P.P., Berger, J. & Hartig, A. (1998) The difference in recognition
of terminal tripeptides as peroxisomal targeting signal 1 between
yeast and human is due to different affinities of their receptor
Pex5p to the cognate signal and to residues adjacent to it. J. Biol.
Chem. 273, 33635–33643.
48. Baes, M., Gressens, P., Baumgart, E., Carmeliet, P., Casteels, M.,

Fransen, M., Evrard, P., Fahimi, D., Declercq, P.E., Collen, D.,
Van Veldhoven, P.P. & Mannaerts, G.P. (1997) A mouse model
for Zellweger syndrome. Nat. Genet 17, 49–56.
49. Tittmann,K.,Mesch,K.,Pohl,M.&Hu
¨
bner, G. (1998) Acti-
vation of thiamine diphosphate carboxylase from Zymomonas
mobilis. FEBS Lett. 441, 404–406.
50. Kern, D., Kern, G., Neef, H., Tittmann, K., Killenberg-Jabs, M.,
Wikner, C., Schneider, G. & Hu
¨
bner, G. (1997) How thiamine
diphosphate is activated in enzymes. Science 275, 67–70.
1626 M. Casteels et al. (Eur. J. Biochem. 270) Ó FEBS 2003
51. Wikner, C., Meshalkina, L., Nilsson, U., Nikkola, M., Lindqvist,
Y., Sunstro
¨
m, M. & Schneider, G. (1994) Analysis of an invariant
cofactor–protein interaction in thiamin diphosphate-dependent
enzymes by site-directed mutagenesis. J. Biol. Chem. 269, 32144–
32150.
52. Jones, J.M., Morell, J.C. & Gould, S.J. (2000) Identification and
characterization of HAOX1, HAOX2, and HAOX3, three human
peroxisomal 2-hydroxy acid oxidases. J. Biol. Chem. 275, 12590–
12597.
53. Jones, J.M., Nau, K., Geraghty, M.T., Erdmann, R. & Gould, S.J.
(1999) Identification of peroxisomal acyl-CoA thioesterases in
yeast and humans. J. Biol. Chem. 274, 9216–9223.
54. Draye, J.P., Van Hoof, F., de Hoffmann, E. & Vamecq, J. (1987)
Peroxisomal oxidation of L-2-hydroxyphytanic acid in rat kidney

cortex. Eur. J. Biochem. 167, 573–578.
55. Verhoeven, N.M., Schor, D.S.M., Previs, S.F., Brunengraber, H.
& Jakobs, C. (1997) Stable isotope studies of phytanic acid
a-oxidation: in vivo production of formic acid. Eur. J. Pediatr. 156,
S83–S87.
56. Mount, S.M. (1982) A catalogue of splice junction sequences.
Nucleic Acid Res. 10, 459–472.
57. Wierzbicki, A.S., Mitchell, J., Lambert-Hammill, M., Hancock,
M., Greenwood, J., Sidey, M.C., de Belleroche, J. & Gibberd, F.B.
(2000) Identification of genetic heterogeneity in Refsum’s disease.
Eur. J. Hum. Genet. 8, 649–651.
58. Van den Brink, D.M., Brites, P., Haasjes, J., Wierzbicki, A.S.,
Mitchell, J., Lambert-Hamill, M., de Belleroche, J., Jansen, G.A.,
Waterham, H.R. & Wanders. (2003) Identification of PEX7 as the
second gene involved in Refsum disease. Am.J.Hum.Genet.72,
471–477.
59. Braverman,N.,Steel,G.,Obie,C.,Moser,A.,Moser,H.,Gould,
S.J. & Valle, D. (1997) Human PEX7 encodes the peroxisomal
PTS2 receptor and is responsible for rhizomelic chondrodysplasia
punctata. Nat. Genet. 15, 369–376.
60. Motley, A.M., Hettema, E.H., Hogenhout, E.M., Brites, P., ten
Asbroek, A.L.M.A., Wijburg, F.A., Baas, F., Heijmans, H.S.,
Tabak, H.F., Wanders, R.J.A. & Distel, B. (1997) Rhizomelic
chondrodysplasia punctata is a peroxisomal protein targeting
disease caused by a non-functional PTS2 receptor. Nat. Genet. 15,
377–380.
61. Purdue, P.E., Zhang, J.W., Skoneczny, M. & Lazarow, P. (1997)
Rhizomelic chondrodysplasia punctata is caused by deficiency of
human PEX7, a homologue of the yeast PTS2 receptor. Nat.
Genet. 15, 381–384.

62. Ferdinandusse, S., Denis, S., Clayton, P.T., Graham, A., Rees,
J.E., Allen, J.T., McLean, B.N., Brown, A.Y.P., Vreken, H.R.,
Waterham, R.J.A. & Wanders. (2000) Mutations in the
gene encoding peroxisomal alpha-methylacyl-CoA racemase
cause adult-onset sensory motor neuropathy. Nat. Genet. 24,188–
191.
63. Song, Q. & Singleton, C.K. (2002) Mitochondria from cultured
cells derived from normal and thiamine-responsive megaloblastic
anemia individuals efficiently import thiamine diphosphate. BMC
Biochem. 3,8.
Ó FEBS 2003 Alpha-oxidation and its TPP dependence (Eur. J. Biochem. 270) 1627